The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

Table 1 Differential gene expression between metastatic melanoma and non-metastatic cutaneous tumors

Gene symbol	Increase in metastatic melanoma relative to		Gene symbol	Decrease in metastatic melanoma relative to
	MIS/Thin	BCC/SCC/MIS/Thin		MIS/Thin	BCC/SCC/MIS/Thin
MAGEA3/A6/A12	125/119/57	27/25/29	CALML5	193	228
MAGEA1/A2/A5	24/57/10	13/31/6	DSC1/3	186/64	198/71
CSAG2	76	36	PKP1	166	240
TRIM51	51	35	CLCA2	162	177
GDF15	30	47	DSG1/3	160/73	178/119
GYPC	18	14	LY6D	143	147
SPP1	15	7	SERPINB3/B5/B7	111/199/106	184/227/144
KIFC1	15	3	C19orf33	122	135
RGS20	14	14	FLG	112	112
C1orf90	13	15	KRT5/16/17	49/111/105	62/196/274
BCL2A1	12	12	KLK7/8/10/11	99/23/27/65	112/32/81/83
SOX5	15	8	LOR	95	98
SLC16A4	12	29	LGALS7	84	89
AKT3	11	9	CST6	82	56
PEG10	11	10	TRIM29	79	119
BUB1	14	3	SFN	77	125
RASGRF1	8	12	ASAH3	69	56
MMP14	8	6	GATA3	63	54
SPRED1	6	4	CBLC	60	64
GPR19	6	5	RAB25	59	78
CDK2	6	7	S100A14/A7/A7L1	27/57/21	44/60/82
HOXA10	3	4	ICEBERG	52	48
HOXB6/7/9	4/5/3	6/7/3	IVL	50	76
HEY1	7	16	ELOVL4	38	34
DUSP4	8	10	CXCL14	36	37
DUSP6	8	6	FOXN1	33	34
CDC45L	7	8	AQP3	29	31
CDC6	9	4	TP73L	29	48
RRM2	6	4	MUC15	25	21
TYMS	4	3	RORA	24	22
BIRC5	4	2	CD24	19	38

The initial statistical analysis addressed the question of whether there were genes differentially expressed (increased or decreased) between primary cancers (BCC/SCC/PCM) and metastatic cancers (metastatic melanoma). Column 1 (MIS/thin) are comprised of only such lesions, while column 2 (BCC/SCC/MIS/Thin) is comprised of all 4 histologic subtypes. All of the annotated genes listed above had a > 2-fold up- or down-regulation in gene expression with the full names of each gene, accession number and gene identification provided in supplementary table 1. Abbreviations: MIS, melanoma-in-situ, BCC, basal cell carcinoma, SCC, squamous cell carcinoma, Thin, thin melanomas < 1.5 mm in Breslow's thickness.

ISSN: 1755-8794